PrecivityAD2 is a blood test cleared in 2026 to help evaluate Alzheimer's disease in adults 40 and older with cognitive symptoms. People with mild cognitive impairment, an early stage of memory or thinking change, can bring specific questions about results, follow-up tests, and care options to a clinician.
On Aug. 20, 2026, C2N Diagnostics announced FDA clearance for use in adults with signs or symptoms of impairment, according to the company clearance announcement. The cleared use includes mild cognitive impairment and excludes screening of healthy adults without symptoms, as reported by Medical Xpress coverage of the clearance.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is the test for?
- What does the score measure?
- How accurate is it?
- What should you ask at the visit?
Who is the test for?
The test is for symptomatic adults age 40 and older being evaluated for Alzheimer's or other cognitive decline. It fits people with noticed memory lapses, word-finding trouble, or reduced planning ability. It does not fit routine checkups for people with no symptoms. A clinician visit still frames the result.
The test is intended for use with clinical assessment, not as population screening or a standalone diagnosis, according to Practical Neurology reporting. Symptoms, history, medicines, and function matter alongside the blood result. A referral question can be direct. Ask whether your symptom pattern qualifies you for testing now. Ask what other workup would happen at the same visit.
What does the score measure?
PrecivityAD2 measures two blood markers tied to Alzheimer's pathology. It uses immunoprecipitation plus LC-MS/MS to measure plasma Aβ42/40 and %p-tau217, per the Mayo Clinic Laboratories test catalog. Those ratios combine into an Amyloid Probability Score 2 from 0 to 100. The score estimates the likelihood of brain amyloid.
A higher score means amyloid is more likely. A lower score means amyloid is less likely. The number alone does not name the cause of impairment. Depression, sleep apnea, thyroid disease, vitamin deficiency, stroke, and medicines can impair thinking. Ask which alternate causes your clinician has ruled out.
How accurate is it?
In a prospective Swedish study of 1,213 patients with cognitive symptoms, APS2 identified Alzheimer pathology with about 90% overall accuracy across primary and specialty care. The study appeared in JAMA, according to the study record in PubMed Central. That result supports use during evaluation, not alone. In that study APS2 at about 91% accuracy outperformed standard evaluation without biomarkers.
Patient Care Online summarized primary-care accuracy as 61% and dementia-specialist accuracy as 73%, in its summary of the JAMA study. The gap explains why a blood marker can change next steps. High-accuracy blood tests have practical weight. The Alzheimer's Association's July 2025 guideline lets high-accuracy tests substitute for PET or spinal-fluid confirmation, while lower-performing tests only triage to PET or spinal fluid, according to Consultant360 coverage of the guideline. Ask where your result falls and whether PET or spinal-fluid testing is still advised.
What should you ask at the visit?
Bring questions that link the score to decisions. The Alzheimer's Association MCI workup suggests asking about confirmatory testing, other causes, medicines or kidney issues, and amyloid-directed care eligibility.
Write answers down or bring a support person. Bring a full medicine list, including sleep aids and allergy drugs. Bring kidney history, recent labs, and examples of daily-task change.
- Do I need PET or spinal-fluid testing to confirm this result?
- What else could explain my impairment besides Alzheimer's?
- Could my medicines, kidney function, or other conditions affect the result?
- Does this result affect eligibility for amyloid-directed care or trials?
- What symptoms, safety issues, and follow-up timing should we track next?
You Might Also Like
- The Long-Term Care Data Cooperative and Dementia Research in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- Electronic Health Records for Dementia Care Research in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- Dementia With Multiple Etiologies in the 2026 NIA Report: A Source-Checked Research Briefing for People With Mild Cognitive Impairment
